Truist Financial
SRPT icon

Truist Financial’s Sarepta Therapeutics SRPT Stock Holding History

Truist Financial’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$306K Buy
17,030
+3,208
+23% +$60.7K ﹤0.01% 2529
2026
Q1 		$301K Sell
13,822
-1,340
-9% -$25.9K ﹤0.01% 2394
2025
Q4 		$326K Buy
15,162
+1,143
+8% +$24.1K ﹤0.01% 2277
2025
Q3 		$270K Buy
+14,019
New +$250K ﹤0.01% 2384
2024
Q4 		– Sell
-1,729
Closed -$216K – 2623
2024
Q3 		$216K Sell
1,729
-2,274
-57% -$314K ﹤0.01% 2308
2024
Q2 		$632K Buy
4,003
+1,857
+87% +$239K ﹤0.01% 1842
2024
Q1 		$278K Sell
2,146
-430
-17% -$52.7K ﹤0.01% 2320
2023
Q4 		$248K Sell
2,576
-168
-6% -$16.1K ﹤0.01% 2411
2023
Q3 		$333K Buy
+2,744
New +$310K ﹤0.01% 2168
2022
Q1 		– Sell
-2,882
Closed -$260K – 2841
2021
Q4 		$260K Sell
2,882
-1,483
-34% -$127K ﹤0.01% 2454
2021
Q3 		$404K Buy
4,365
+1,425
+48% +$110K ﹤0.01% 2134
2021
Q2 		$229K Sell
2,940
-1,599
-35% -$121K ﹤0.01% 2528
2021
Q1 		$339K Sell
4,539
-5,691
-56% -$525K ﹤0.01% 2209
2020
Q4 		$1.74M Sell
10,230
-2,670
-21% -$396K ﹤0.01% 1234
2020
Q3 		$1.81M Buy
12,900
+4,709
+57% +$716K ﹤0.01% 1111
2020
Q2 		$1.31M Buy
8,191
+121
+1% +$16.5K ﹤0.01% 1177
2020
Q1 		$790K Sell
8,070
-1,609
-17% -$184K ﹤0.01% 1355
2019
Q4 		$1.25M Buy
9,679
+5,163
+114% +$521K ﹤0.01% 1346
2019
Q3 		$340K Buy
4,516
+111
+3% +$13.1K 0.01% 647
2019
Q2 		$669K Buy
4,405
+143
+3% +$17.4K 0.01% 522
2019
Q1 		$508K Buy
4,262
+468
+12% +$60.2K 0.01% 571
2018
Q4 		$414K Buy
3,794
+307
+9% +$38.4K 0.01% 578
2018
Q3 		$563K Buy
3,487
+504
+17% +$68.9K 0.01% 563
2018
Q2 		$394K Buy
+2,983
New +$281K 0.01% 630

Other funds holding SRPT

EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
GIC
Generali Investments CEE Prague, Czech Republic $2.11B AUM 25.53% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
OAM
OP Asset Management Helsinki $9.38B AUM 42.35% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

Truist Financial's SRPT Position: Q2 2026 in Review

Truist Financial increased its Sarepta Therapeutics (SRPT) stake by 23% in Q2 2026, buying an estimated $60.7K and bringing the position to 17,030 shares worth $306K. The position accounts for ﹤0.01% of the portfolio, ranked #2529.

Truist Financial first reported a position in SRPT in Q2 2018 and has held it in 24 quarters since. The position peaked at $1.81M in Q3 2020. 72 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Truist Financial held 17,030 shares of Sarepta Therapeutics worth $306K as of Q2 2026.
  • Truist Financial bought 3,208 Sarepta Therapeutics shares in Q2 2026, an estimated $60.7K.
  • Sarepta Therapeutics made up ﹤0.01% of Truist Financial's portfolio in Q2 2026, its #2529 holding.
  • Truist Financial first reported a position in Sarepta Therapeutics in Q2 2018 and has held it in 24 quarters since.
  • Truist Financial's Sarepta Therapeutics position peaked at $1.81M in Q3 2020.
  • 72 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Truist Financial's 13F filing for Q2 2026, filed 28 Jul 2026.